Private EquityRIA · CRD 174588Exempt Reporting AdviserPrivate Fund Adviser

Updated:

Kester Capital

Kester Capital partners with ambitious Technology and Life Sciences businesses to help them achieve their potential. The firm seeks out ambitious companies and...

Kester Capital logo

Kester Capital

Kester Capital partners with ambitious Technology and Life Sciences businesses to help them achieve their potential. The firm seeks out ambitious companies and dynamic leaders who want to scale faster, targeting equity investments of up to £75 million. It focuses on only two sectors—Technology and Life Sciences—and aims to build strong, lasting relationships with the teams it backs based on transparency, integrity and teamwork.

General information

Firm type

Private Equity

Year founded

2006

Location

Region

Europe

Country

United Kingdom

City

London

Corporate office

London, United Kingdom

Principals

Michael Lemoru

Vice President

Max Jackson

Principal

Sector focus

Enterprise SoftwareDigital HealthHealthcare Services

Frequently asked questions

What is Kester Capital's typical investment size and structure?

Kester writes primary equity cheques of £10m to £30m for majority control. The firm targets UK-headquartered businesses with enterprise values generally in the £10m to £50m range. Every transaction is structured as a controlling buyout, often with the founder retaining a significant co-investment stake and rolling equity alongside Kester's platform vehicle.

Is Kester Capital raising institutional capital now?

Kester closed its third institutional fund at a hard cap of roughly £150m in 2022. Based on its prior fundraising cadence of approximately four years between vintages, a successor fund is unlikely to enter the market before late 2025 at the earliest. No Form D equivalent filing currently signals active fundraising.

What is Kester Capital's realised track record?

The firm has reported top-quartile net IRRs across its fund series, with two strong exits in the public domain. Its sale of JensonR+, a compliance-software business, generated a reported return above 3x multiple on invested capital. Separately, a regulatory technology asset was sold to a European trade buyer at a similar multiple. These two deals anchor Kester's claims of pricing discipline and operational value creation.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More London Private Equity profiles